Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients

Genet Mol Res. 2015 Aug 21;14(3):10081-6. doi: 10.4238/2015.August.21.15.

Abstract

We investigated the association between plasminogen activator inhibitor-1 (PAI-1) polymorphisms and plasma PAI-1 level with sepsis in severely burned patients. A total of 182 patients with burn areas lager than 30% of the body surface area were enrolled in this study. Peripheral blood samples were obtained from 103 patients with sepsis (sepsis group) and 79 patients without sepsis (control group). An allele-specific polymerase chain reaction assay was used to determine PAI-1 polymorphism 4G/5G distribution. Plasma PAI-1 levels were detected using an enzyme-linked immunosorbent assay. The frequency of the 4G/4G genotype and the 4G allele frequency in the sepsis group were 42.7 and 62.1% respectively, which were significantly higher than those in the control group (P < 0.05). Sepsis patients had a significantly higher plasma PAI-1 level than the control group (P < 0.05). Compared with the 5G/5G genotype, PAI-1 concentrations were significantly higher in the 4G/4G genotype (P < 0.05). The study indicates that the 4G/5G promoter polymorphism of PAI-1 gene may be related to the susceptibility to burn sepsis and that the 4G/4G genotype may be an important genetic risk factor of burn sepsis. Additionally, PAI-1 concentrations in the serum are increased in patients with burn sepsis.

MeSH terms

  • Adult
  • Alleles
  • Burns / complications*
  • Burns / diagnosis
  • Disease Susceptibility
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Genotype
  • Humans
  • Male
  • Plasminogen Activator Inhibitor 1 / blood*
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic*
  • Polymorphism, Single Nucleotide
  • Sepsis / blood*
  • Sepsis / etiology*
  • Severity of Illness Index
  • Young Adult

Substances

  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human